Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
Karim SP, Adelman RA. Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy. Clinical Ophthalmology 2013, Volume 7: 1867-1875. PMID: 24092965, PMCID: PMC3788817, DOI: 10.2147/opth.s32177.Peer-Reviewed Original ResearchCentral serous chorioretinopathySerous chorioretinopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsSafety of PDTTreatment of CSCRPhotodynamic therapyChronic recurrent formGrowth factor agentsPermanent visual lossPossible pathophysiologic mechanismsSerous retinal detachmentProspective interventional studyLong-term efficacyPigment epithelial detachmentPotential therapeutic optionEfficacy of PDTMajority of casesFactor agentsAnatomic improvementFoveal atrophyPigment epitheliopathyRetinal detachmentVisual lossFluorescein angiographyIncidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents
Abedi G, Adelman RA, Salim S. Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents. Seminars In Ophthalmology 2013, 28: 126-130. PMID: 23631423, DOI: 10.3109/08820538.2013.771195.Peer-Reviewed Original ResearchConceptsPersistent ocular hypertensionIntraocular pressureOcular hypertensionIntravitreal antivascular endothelial growth factorAntivascular endothelial growth factor agentsChronic intraocular pressure elevationEndothelial growth factor agentsIntravitreal anti-VEGF injectionsAntivascular endothelial growth factorAnti-VEGF injectionsGrowth factor agentsIntraocular pressure elevationElevated intraocular pressureElectronic literature searchEndothelial growth factorKey search termsFactor agentsPrompt diagnosisVEGF injectionAcute elevationIntravitreal injectionIOP elevationPersistent elevationPressure elevationGlaucomatous eyes